Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 5/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23214655 | 0.81 | LMNA (0.43) | LMNATSHRHSD17B10HPGDALOX15 | |
| SCHEMBL23214644 | 0.78 | LMNA (0.47) | LMNATSHRHSD17B10HPGDALOX15 | |
| SCHEMBL10702604 | 0.72 | LMNA (0.72) | LMNATSHRHSD17B10HPGDALOX15 | |
| SCHEMBL26771218 | 0.71 | LMNA (0.44) | LMNATSHRHSD17B10HPGDALOX15 | |
| SCHEMBL4060593 | 0.69 | LMNA (0.42) | LMNATSHRHSD17B10HPGDALOX15 | |
| SCHEMBL8350553 | 0.69 | TSHR (0.46) | LMNATSHRHSD17B10HPGDALOX15 | |
| SCHEMBL29768386 | 0.69 | LMNA (0.36) | LMNATSHRHSD17B10HPGDALOX15 | |
| SCHEMBL21302114 | 0.68 | LMNA (0.50) | LMNATSHRHSD17B10HPGDALOX15 | |
| SCHEMBL16736873 | 0.68 | RORC (0.49) | LMNATSHRHSD17B10HPGDALOX15 | |
| SCHEMBL6643908 | 0.67 | NISCH (0.44) | LMNATSHRCYP3A4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220411367-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC | 2022-12-29 | — | — | US | disclosed |
| EP-4041228-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D.E. Shaw Research, LLC (US) | 2022-08-17 | — | — | EP | disclosed |
| CN-114727993-A | Arylmethylene heterocyclic compounds as Kv1.3 potassium SHAKER channel blockers | D·E·萧尔研究有限责任公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2021071812-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D.E SHAW RESEARCH, LLC (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021071812-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D.E SHAW RESEARCH, LLC (US) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411367-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | KCNJ2, KCNA3, KCNH3 | LMNA 1864/4885TSHR 2041/4885HSD17B10 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.